All three risk analysts converge on Hold, which validates the verdict — CVS sits in a "no-man's land" zone between lower-Bollinger resistance and mid-range support, so do not chase at $95.70. Accumulate only on weakness toward $90.50 with stop at $83.90 (just below the 200-DMA at $83.93), and scale up on capitulation flush to $88-90 or successful 50-day SMA reclaim at $101.40; the 2.76% dividend makes the wait productive.